专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011096196A1 LSD1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： LSD1用于靶向治疗癌症和诊断基因
公开(公告)号：WO2011096196A1
公开(公告)日：2011-08-11
申请号：PCT/JP2011/000551
申请日：2011-02-01
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61P15/00 , C12Q1/02 , C12Q1/68
CPC分类号： A61K31/713 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/57484 , G01N2333/90245 , G01N2500/04
摘要： The present invention relates to the roles played by a LSD1 gene in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the LSD1 gene or a composition, vector or cell containing such a double- stranded molecule. The present invention also features methods and kits for detecting or diagnosing cancer in a subject, using the over-expressed LSD1 gene. Also, disclosed are methods of screening for candidate substances for treating and preventing cancer or inhibiting cancer cell growth, using as an index their effect on the expression or activity of LSD1.
摘要翻译：本发明涉及LSD1基因在癌发生中的作用，特征在于通过对LSD1基因施用双链分子或含有这种双链分子的组合物，载体或细胞来治疗或预防癌症的方法。本发明还涉及使用过表达的LSD1基因来检测或诊断受试者中的癌症的方法和试剂盒。还公开了使用作为LSD1的表达或活性的指标的指标来筛选用于治疗和预防癌症或抑制癌细胞生长的候选物质的方法。

2. 发明申请

WO2012144220A1 EZH2 AS TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： EZH2作为目标基因用于癌症治疗和诊断
公开(公告)号：WO2012144220A1
公开(公告)日：2012-10-26
申请号：PCT/JP2012/002721
申请日：2012-04-19
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12Q1/68 , A61K31/7105 , A61K48/00 , C12N15/09
CPC分类号： C12Q1/6886 , A61K31/7105 , C12N15/113 , C12N2310/14 , C12Q2600/158 , C12N2310/531
摘要： The present invention provides methods for detecting and diagnosing cancer, such methods involving the determination of the expression level of the EZH2 gene. The present invention also provides methods for determining or assessing the prognosis of cancer based on the expression level of the EZH2 gene. Furthermore, the present invention provides methods of screening for therapeutic agents useful in either or both of the treatment and prevention of cancer and methods for either or both of treating and preventing cancer. Moreover, the present invention provides double-stranded molecules targeting the EZH2 gene, all of which are suggested to be useful in either or both of the treatment and prevention of cancer.
摘要翻译：本发明提供了检测和诊断癌症的方法，涉及确定EZH2基因表达水平的方法。本发明还提供了基于EZH2基因的表达水平来确定或评估癌症预后的方法。此外，本发明提供了筛选用于治疗和预防癌症的治疗剂的方法和用于治疗和预防癌症的方法之一。此外，本发明提供靶向EZH2基因的双链分子，所有这些都被认为可用于治疗和预防癌症中的一种或两种。

3. 发明申请

WO2012090479A1 MCM7 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： MCM7作为癌症治疗和诊断的靶基因
公开(公告)号：WO2012090479A1
公开(公告)日：2012-07-05
申请号：PCT/JP2011/007285
申请日：2011-12-27
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61K48/00 , C12Q1/02 , C12Q1/68
CPC分类号： C12Q1/6886 , A61K31/713 , C12N15/113 , C12N2310/14 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57488 , G01N2500/04 , G01N2500/10 , G01N2800/50
摘要： The present invention relates to the discovery that the MCM7 gene can discriminate cancer cells from normal cells. Accordingly, the present invention provides methods for detecting or diagnosing cancer in a subject or a predisposition for developing cancer or assessing or determining the prognosis for a subject so diagnosed using the expression level of the MCM7 genes as an index of disease. The present invention also provides methods of screening for therapeutic agents useful in the treatment of cancer and methods for treating cancer, particularly double-stranded molecules targeting the MCM7 suggested to be useful in the treatment of cancer.
摘要翻译：本发明涉及MCM7基因能够区分癌细胞与正常细胞的发现。因此，本发明提供了用于检测或诊断受试者中的癌症或用于发展癌症的倾向性的方法，或者使用MCM7基因的表达水平作为疾病指标来评估或确定如此诊断的受试者的预后。本发明还提供筛选用于治疗癌症的治疗剂的方法和用于治疗癌症的方法，特别是靶向建议可用于治疗癌症的MCM7的双链分子。

4. 发明申请

WO2010095364A1 JARID1B FOR TARGET GENE OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： JARID1B针对目标癌基因治疗和诊断
公开(公告)号：WO2010095364A1
公开(公告)日：2010-08-26
申请号：PCT/JP2010/000441
申请日：2010-01-27
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , HAMAMOTO, Ryuji , TSUNODA, Takuya
发明人： NAKAMURA, Yusuke , HAMAMOTO, Ryuji , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61P35/00 , C12N15/113 , C12Q1/68 , G01N33/15
CPC分类号： A61K31/713 , C12N15/113 , C12N2310/14 , C12Q1/48 , C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , G01N33/574 , G01N2333/91011 , G01N2500/00
摘要： The present invention relates to the roles played by the JARID1B genes in cancers and features a method for treating cancers by administering a composition comprising a double-stranded molecule against the JARID1B genes or a vector encoding them. The present invention also features methods for diagnosing cancers by detecting the expression of JARID1B. To that end, JARID1B serves as a serological biomarker for cancers. Also, disclosed are methods of identifying candidate agents for treating or preventing cancer or inhibiting cancer cell growth, using the expression of JARID1B in the cancer cells or the cell proliferation resulted from expression of JARID1B as an index.
摘要翻译：本发明涉及JARID1B基因在癌症中的作用，其特征在于通过对JARID1B基因或编码它们的载体施用包含双链分子的组合物来治疗癌症的方法。本发明还具有通过检测JARID1B的表达来诊断癌症的方法。为此，JARID1B作为癌症的血清学生物标志物。还公开了使用JARID1B在癌细胞中的表达或由JARID1B表达作为指标导致的细胞增殖来鉴定用于治疗或预防癌症或抑制癌细胞生长的候选药剂的方法。

5. 发明申请

WO2013080400A1 SMYD2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SMYD2作为癌症治疗和诊断的靶基因
公开(公告)号：WO2013080400A1
公开(公告)日：2013-06-06
申请号：PCT/JP2012/004232
申请日：2012-06-29
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12Q1/68 , C12N15/09 , G01N33/15 , G01N33/574
CPC分类号： G01N33/57484 , C12Q1/689 , C12Q2600/158 , G01N33/57407
摘要： The present invention arises from the discovery that the SMYD2 gene is both specifically over-expressed in cancer and involved in cancer cell survival. The present invention features methods for detecting or diagnosing the presence of or predisposition for developing cancer, using the SMYD2 gene as a diagnostic marker. The present invention further provides methods of screening for therapeutic substances useful in either or both of the treatment and prevention of cancer.
摘要翻译：本发明是由SMYD2基因在癌症中特异性过度表达并参与癌细胞存活的发现而产生的。本发明的特征在于使用SMYD2基因作为诊断标记来检测或诊断发展中的癌症的存在或倾向的方法。本发明还提供筛选用于治疗和预防癌症的治疗物质的方法。

6. 发明申请

WO2012164936A1 SUV39H2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SUV39H2作为癌症治疗和诊断的靶基因
公开(公告)号：WO2012164936A1
公开(公告)日：2012-12-06
申请号：PCT/JP2012/003569
申请日：2012-05-31
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61K48/00 , A61P35/00 , C12N15/113 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/574
CPC分类号： C12Q1/6886 , C12N15/1137 , C12N2310/14 , C12Q1/48 , C12Q2600/136 , C12Q2600/158 , C12Y201/01043 , G01N33/5011 , G01N33/57407 , G01N33/57411 , G01N33/57423 , G01N33/57434 , G01N2500/04
摘要： Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer. The present invention also features double-stranded molecules against the SUV39H2 gene and vectors encoding thereof as well as compositions containing such components and their utility in connection with the treatment and prevention of an SUV39H2-associated cancer.
摘要翻译：本文描述了用于检测或诊断癌症或确定发展癌症，特别是肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤的倾向的客观方法。在一个实施方案中，诊断方法包括确定SUV39H2基因的表达水平。本发明还提供了筛选用于治疗和/或预防SUV39H2相关癌症（例如肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤）的候选物质的方法。本发明还提供了抑制细胞生长，从而治疗或减轻SUV39H2相关癌症症状的方法。本发明还具有针对SUV39H2基因的双链分子及其编码载体以及含有这些组分的组合物及其与治疗和预防SUV39H2相关癌症有关的用途。

7. 发明申请

WO2011096210A1 PRMT1 AND PRMT6 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： PRMT1和PRMT6用于癌症治疗和诊断的目标基因
公开(公告)号：WO2011096210A1
公开(公告)日：2011-08-11
申请号：PCT/JP2011/000582
申请日：2011-02-02
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61P35/00 , C12Q1/68
CPC分类号： A61K31/713 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 or PRMT6 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 or PRMT6 associated diseases, such as a cancer, e.g., bladder cancer, diffuse-type gastric cancer, breast cancer, esophageal cancer, NSCLC, SCLC, lymphoma, pancreatic cancer, testicular cancer, cervical cancer, osteosarcoma, prostate cancer and CML. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 or PRMT6 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions containing them.
摘要翻译：本文描述了用于诊断发展中的癌症，特别是膀胱癌，胃癌，结肠直肠癌，乳腺癌，食管癌，肺癌，淋巴瘤，胰腺癌和睾丸癌的倾向的客观方法。在一个实施方案中，诊断方法包括确定PRMT1或PRMT6基因的表达水平。本发明还提供筛选用于治疗PRMT1或PRMT6相关疾病的治疗剂的方法，例如癌症，例如膀胱癌，弥漫性胃癌，乳腺癌，食管癌，NSCLC，SCLC，淋巴瘤，胰腺癌，睾丸癌，子宫颈癌，骨肉瘤，前列腺癌和CML。本发明还提供抑制细胞生长和治疗或减轻PRMT1或PRMT6相关疾病症状的方法。本发明还包括产物，包括双链分子和编码它们的载体以及含有它们的组合物。

8. 发明申请

WO2012023287A1 SUV420H1 AND SUV420H2 AS TARGET GENES FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SUV420H1和SUV420H2作为癌症治疗和诊断的靶基因
公开(公告)号：WO2012023287A1
公开(公告)日：2012-02-23
申请号：PCT/JP2011/004620
申请日：2011-08-18
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61P35/00 , C12N15/113 , G01N33/15 , G01N33/50
CPC分类号： G01N33/5011 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12Q1/48 , C12Q1/6897 , C12Y201/01043 , G01N33/57407 , G01N33/6872 , G01N2500/04
摘要： The present invention relates to the roles played by the SUV420H1 and SUV420H2 genes in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the SUV420H1 or SUV420H2 gene or a composition or vector containing such a double-stranded molecule. The present invention also features methods and kits for detecting or diagnosing cancer in a subject, including detecting an expression level of the SUV420H1 or SUV420H2 gene. The present invention further features methods and kits for assessing or determining the prognosis of a subject with cancer, including detecting the expression level of an SUV420H2 gene. Also, disclosed are methods of screening for candidate substances for treating or preventing cancer or inhibiting cancer cell growth, using as an index their effect on the expression or activity of SUV420H1 or SUV420H2.
摘要翻译：本发明涉及SUV420H1和SUV420H2基因在癌发生中的作用，其特征在于通过对SUV420H1或SUV420H2基因施用双链分子或含有这种双链分子的组合物或载体来治疗或预防癌症的方法。本发明还特征在于检测或诊断受试者的癌症的方法和试剂盒，包括检测SUV420H1或SUV420H2基因的表达水平。本发明还涉及用于评估或确定患有癌症的受试者的预后的方法和试剂盒，包括检测SUV420H2基因的表达水平。此外，公开了使用作为SUV420H1或SUV420H2的表达或活性的指标作为指标来筛选用于治疗或预防癌症或抑制癌细胞生长的候选物质的方法。

9. 发明申请

WO2012023285A1 EHMT2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： EHMT2作为癌症治疗和诊断的靶基因
公开(公告)号：WO2012023285A1
公开(公告)日：2012-02-23
申请号：PCT/JP2011/004608
申请日：2011-08-17
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12Q1/68 , A61K31/498 , A61K31/7088 , A61K45/00 , A61K48/00 , A61P35/00 , C12N15/09 , C12Q1/02 , C12Q1/48 , G01N33/53
CPC分类号： C12Q1/48 , A61K31/5513 , A61K31/713 , C12Q1/6886 , C12Q2527/125 , C12Q2600/136 , C12Q2600/158 , G01N2333/91011 , G01N2500/04 , G01N2500/10 , G01N2800/50 , G01N2800/7028
摘要： Objective methods for diagnosing a predisposition to developing cancer, including bladder cancer, lung cancer, AML, CML, esophageal cancer, breast cancer, cervical cancer and osteosarcoma caner is described herein. The present invention provides a diagnostic method that utilizes the expression level of EHMT2 as an index of cancer. The present invention further provides methods of screening for therapeutic substances for the treatment of EHMT2-associated disease, such as a cancer, e.g. bladder cancer, lung cancer, AML, CML, esophageal cancer, breast cancer, cervical cancer and osteosarcoma. The invention further provides methods of inhibiting cell growth and treating or alleviating one or more symptoms of EHMT2-associated diseases. The invention also features double-stranded molecules that inhibit EHMT2 expression, vectors encoding the double-stranded molecule and compositions containing them.
摘要翻译：本文描述了用于诊断发展中的癌症的倾向的客观方法，包括膀胱癌，肺癌，AML，CML，食管癌，乳腺癌，子宫颈癌和骨肉瘤。本发明提供了利用EHMT2的表达水平作为癌症指标的诊断方法。本发明还提供筛选用于治疗EHMT2相关疾病（例如癌症）的治疗物质的方法。膀胱癌，肺癌，AML，CML，食管癌，乳腺癌，子宫颈癌和骨肉瘤。本发明还提供抑制细胞生长和治疗或减轻EHMT2相关疾病的一种或多种症状的方法。本发明还具有抑制EHMT2表达的双链分子，编码双链分子的载体和含有它们的组合物。

10. 发明申请

WO2011096211A1 WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： WHSC1和WHSC1L1用于靶向治疗癌症和诊断基因
公开(公告)号：WO2011096211A1
公开(公告)日：2011-08-11
申请号：PCT/JP2011/000585
申请日：2011-02-02
申请人： ONCOTHERAPY SCIENCE, INC. , HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： HAMAMOTO, Ryuji , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61P35/00 , C12Q1/68
CPC分类号： C12N15/1137 , A61K31/713 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/53
摘要： Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide.
摘要翻译：用于诊断发展中癌症的倾向的客观方法，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤，在此描述。在一个实施方案中，诊断方法包括确定WHSC1或WHSC1L1基因的表达水平。本发明还提供筛选用于治疗WHSC1或WHSC1L1相关疾病的治疗剂的方法，例如癌症，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤。本发明还提供抑制细胞生长和治疗或减轻WHSC1或WHSC1L1相关疾病症状的方法。本发明还包括产物，包括双链分子和编码它们的载体以及包括它们的组合物。此外，公开了用于鉴定用于治疗或/和预防肺癌的物质的方法，以其对WHSC1或WHSC1L1基因表达的影响或WHSC1或WHSC1L1多肽的生物活性的指标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式